This page collects WhisperX intelligence signals tagged #FDA. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Pharmaceutical giants are systematically exploiting the FDA’s Accelerated Approval pathway to shield lucrative drugs from market withdrawal, internal regulatory communications reveal. Companies are granted early approval based on surrogate endpoints, with a strict mandate to conduct post-market confirmatory trials. How...
Internal FDA communications and whistleblower leaks reveal a systemic exploitation of the Accelerated Approval pathway by US pharmaceutical giants. Companies are intentionally delaying mandatory confirmatory clinical trials for oncology drugs, allowing them to market unproven, high-cost therapies for years. When prelim...
Internal SEC filings and whistleblower reports have revealed that a prominent US biotech firm systematically manipulated clinical trial data for a highly touted Alzheimer's drug. Executives allegedly altered Western blot images to fabricate efficacy while suppressing negative safety signals submitted to the FDA. Despit...
A joint congressional investigation has exposed unprecedented collusion between the FDA and Biogen to push through the controversial Alzheimer's drug Aduhelm. Internal communications and whistleblower testimonies reveal that FDA officials and Biogen executives engaged in dozens of undocumented "off-the-books" meetings,...
Despite federal mandates, a massive loophole in FDA oversight has allowed US pharmaceutical companies and research universities to hide results for thousands of clinical trials. Internal compliance data reveals that the FDA has issued barely a fraction of the required noncompliance notices, effectively shielding the in...
Whispers from within a major US pharmaceutical firm suggest critical adverse event data from a Phase III clinical trial for a widely prescribed cardiovascular medication was deliberately downplayed and partially omitted from regulatory submissions. Sources indicate the internal review flagged a statistically significan...
Whispers from within a major US pharmaceutical firm suggest that crucial data from Phase III clinical trials for a widely prescribed cardiovascular drug was deliberately downplayed and omitted from regulatory submissions. Sources indicate that a subset of patients experienced severe, unexpected adverse events, includin...
A significant conflict of interest is emerging within the Food and Drug Administration (FDA) concerning a review of new warnings for antidepressant drugs. A top FDA drug official is attempting to hire a personal friend who is actively seeking the implementation of a bold new warning label for these medications. This si...
The Food and Drug Administration (FDA) is currently reviewing a formal request to implement new, bold warnings on antidepressant medications. This review process has triggered an unusual and significant conflict of interest within the agency. The situation centers on a top FDA drug official who is actively attempting t...
The U.S. Food and Drug Administration (FDA) has taken regulatory action against 30 telehealth companies, issuing formal warning letters concerning their marketing and promotion of compounded versions of popular glucagon-like peptide-1 (GLP-1) agonist drugs, such as Ozempic (semaglutide) and Zepbound (tirzepatide). The ...
The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their 'illegal' sales of compounded GLP-1s, building off increasing pressure to tamp down on the unauthorized distribution of these popular weight-loss and diabetes drugs. The agency stated these companies are illegally...
A significant controversy is emerging within the U.S. Food and Drug Administration (FDA) concerning a new warning on antidepressant use during pregnancy. Dr. Tracy Beth Hoeg, a top FDA regulator, is accused of bypassing standard agency recusal rules to improperly advance a personal and professional agenda. The allegati...
The U.S. Food and Drug Administration (FDA) has issued a second formal warning letter to pharmaceutical giant Novo Nordisk regarding its promotional activities for the GLP-1 drug Ozempic (semaglutide). The regulatory action cites violations related to misleading claims and inadequate risk disclosure in the company's ad...
The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding a potential safety issue with certain Impella heart pump devices manufactured by Abiomed. The alert concerns the differential pressure sensor within the devices, which may malfunction. Specifically, the sensor values are reported to potenti...
Integra LifeSciences Holdings Corporation has initiated a recall of all MediHoney Wound and Burn Dressing products and specific lots of CVS Wound Gel. The recall, classified by the FDA as a Class I recall—the most serious type—is due to a potential breach of the product's sterile barrier. A breach in the sterile barrie...
The U.S. Food and Drug Administration (FDA) has issued a MedWatch Early Alert regarding a potential safety issue with the Vantive Prismaflex Set, a dialysis tubing set. The alert identifies a specific problem: the deaeration chambers within the Prismaflex Set may dislodge from the Prismaflex Control Unit during clinica...
Rosemead, CA – ANTHONY TRINH, 123herbals LLC is voluntarily recalling all lots of Silintan capsules to the consumer level. The recall was initiated after FDA analysis found the product to be tainted with meloxicam. Meloxicam is an approved Nonsteroidal Anti-Inflammatory Drug (NSAID) indicated for the management of oste...
Fresenius Kabi has initiated a software correction for its Ivenix Large Volume Infusion Pump (LVP) system. The action is being taken in response to identified software anomalies that, if they occur, could lead to serious patient harm or death. The specific nature of the software anomalies was not detailed in the initia...
The U.S. Food and Drug Administration (FDA) has issued an early alert regarding a safety issue with the Impella Generation 1 Purge Cassettes manufactured by Abiomed. The identified problem is an increased risk of purge leaks within the cassette system. These leaks can compromise the device's function by leading to low ...
Johnson & Johnson's MedTech division, operating through its CERENOVUS Inc. subsidiary, has initiated a removal of its CEREPAK Detachable Coil System from the market. The action is being taken in response to a higher-than-expected rate of device failure, specifically a failure of the coil to detach from its delivery sys...